尽管出现亏损和核心业务下降，但由于美国大麻改革的希望，Tilray 股价自 7 月以来飙升了 300%。 Tilray stock soared 300% since July on U.S. cannabis reform hopes, despite losses and declining core business.

自7月以来,Tilray Brands(TLRY)的库存由于美国大麻改革的希望而猛增了300%,尽管该公司最近一个财政年度仍然无利可图,业务损失1.747亿美元,尽管4%的收入增加到8.213亿美元。 Tilray Brands (TLRY) stock surged 300% since July on hopes of U.S. cannabis reform, though the company remains unprofitable with a $174.7 million operating loss in its latest fiscal year, despite a 4% revenue increase to $821.3 million. 其核心大麻业务下降了9%,增长依赖酒精和健康方面的收购。 Its core cannabis business declined 9%, and growth has relied on acquisitions in alcohol and wellness. 收益将于2025年10月9日到期, 过去的报道引发了抛售, 在美国合法化和银行改革努力停滞的情况下, 发布前引发了担忧. Earnings are due October 9, 2025, and past reports have triggered sell-offs, raising concerns ahead of the release amid stalled U.S. legalization and banking reform efforts.